Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1820237 alone or with semaglutide/survodutide in obesity
NCT05751226Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1820237 in obesity (6 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of treatment-emergent adverse events at 180 days. Started Apr 2023; status: completed.
02
Drugs
BI 1820237
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05751226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751226.